Therapeutic Area

Metabolic Disorders

Therapeutic area intelligence for Metabolic Disorders with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 5
Catalysts: 0
Companies: 2

Companies

Aurobindo Pharma →

Teva →

Assets

Recent signals(5)

RegulatoryJuly 4, 2026

Aurobindo Pharma's Glycerol Phenylbutyrate Application Receives FDA Review

Aurobindo Pharma has submitted an original application for Glycerol Phenylbutyrate under ANDA220313, which is currently under standard review by the FDA.

RegulatoryJuly 4, 2026

FDA Grants Approval for Glycerol Phenylbutyrate ANDA219540

The FDA has granted approval for the ANDA219540 application for Glycerol Phenylbutyrate submitted by MSN.

RegulatoryJuly 4, 2026

FDA Grants Approval for Sodium Bicarbonate ANDA220788 by ASPIRO

The FDA has granted approval for ANDA220788, a sodium bicarbonate formulation submitted by ASPIRO.

RegulatoryJuly 3, 2026

Teva's Glycerol Phenylbutyrate ANDA218738 Receives AP Status from FDA

Teva Pharmaceuticals has received an Abbreviated New Drug Application (ANDA) approval status for Glycerol Phenylbutyrate.

ClinicalJune 26, 2026

Akkermansia muciniphila MucT shows potential in improving insulin sensitivity in metabolic syndrome

A double-blind trial indicated that pasteurized Akkermansia muciniphila MucT improved insulin sensitivity and GLP-1 production in specific subgroups of adults with metabolic syndrome.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Metabolic Disorders →

Urea Cycle Disorder →

Urea Cycle Disorders →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.